Skip to content
Screener

Bausch + Lomb BLCO Financing Cash Flow

Financing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
-$75.8M-781%
Glaukos logo
GlaukosGKOS
$991K-55.9%
LENSAR, Inc. logo
LENSAR, Inc.LNSR
-$209K-102%
HRO
HarrowHROW
$48.91M+212,561%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$294K-93.0%

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$5.84B+17.0%
Enterprise value$10.54B+8.9%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from exercise of stock options2
Payments of financing costs(10)
Payments of noncontrolling interest distributions(7)(9)
Net cash provided by financing activities14121
Effect of exchange rate changes on cash and cash equivalents and restricted cash(1)31
Net decrease in cash and cash equivalents and restricted cash(19)(44)
Cash and cash equivalents and restricted cash, beginning of period397316
Cash and cash equivalents and restricted cash, end of period$378$272

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's financing cash flow?
Bausch + Lomb (BLCO) reported financing cash flow of $34M in Q2 2026.
How has Bausch + Lomb's financing cash flow changed year-over-year?
Bausch + Lomb's financing cash flow decreased by 62.2% year-over-year, from $90M to $34M.
What is the long-term trend for Bausch + Lomb's financing cash flow?
Over 2 years (2021 to 2025), Bausch + Lomb's financing cash flow has grown at a -42.3% compound annual growth rate (CAGR), from -$712M to $237M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Bausch + Lomb's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude